ClinicaliQ Trial Snapshot
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma — Active Not Recruiting • Phase I • Oncology • NCT04722146.
- Trial testing whether teclistamab combined with other cancer drugs is safe and effective for multiple myeloma patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens. Conditions: Multiple Myeloma Interventions: Teclistamab, Daratumumab, Pomalidomide, Lenalidomide, Bortezomib, Nirogacestat Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 140 participants